Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Merck KGaA describes new derivatives of the kappa opioid agonist asimadoline

Aug. 5, 2004

Toll-like receptor 4 antagonist promising against IBD in mice

Aug. 3, 2004

Phase II study evaluates IDN-6556 in HCV patients

Aug. 3, 2004

Phase I results of spi-VEC vaccine for hepatitis B

July 30, 2004

Launch of Axid oral solution

July 30, 2004

URSO 500 mg approved for primary biliary cirrhosis

July 28, 2004

Intercell's phase II study of hepatitis C vaccine meets endpoints

July 28, 2004

Gilead claims new anti-HBV/HDV agents

July 28, 2004

FDA approves Alinia tablets for adults

July 27, 2004

Isis scientists describe new anti-HCV agents targeting IRES

July 27, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...